<code id='BEC477448C'></code><style id='BEC477448C'></style>
    • <acronym id='BEC477448C'></acronym>
      <center id='BEC477448C'><center id='BEC477448C'><tfoot id='BEC477448C'></tfoot></center><abbr id='BEC477448C'><dir id='BEC477448C'><tfoot id='BEC477448C'></tfoot><noframes id='BEC477448C'>

    • <optgroup id='BEC477448C'><strike id='BEC477448C'><sup id='BEC477448C'></sup></strike><code id='BEC477448C'></code></optgroup>
        1. <b id='BEC477448C'><label id='BEC477448C'><select id='BEC477448C'><dt id='BEC477448C'><span id='BEC477448C'></span></dt></select></label></b><u id='BEC477448C'></u>
          <i id='BEC477448C'><strike id='BEC477448C'><tt id='BEC477448C'><pre id='BEC477448C'></pre></tt></strike></i>

          focus

          focus

          author:fashion    Page View:89753
          Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC.
          Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

          WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

          Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

          advertisement

          The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Personalized medicine goes far beyond genetics
          Personalized medicine goes far beyond genetics

          AdobeSincetheHumanGenomeProjectwascompletedin2003,mostpublicconsiderationsofpersonalizedmedicinehave

          read more
          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more

          The cancer stories no one wants to hear

          KARL-JOSEFHILDENBRAND/AFP/GettyImagesDuringthe11monthswhenmyhusband,Ahmad,wasdyingofbladdercancer,fe